Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Delenex Therapeutics AG Snapshot 5 Delenex Therapeutics AG Overview 5 Key Information 5 Key Facts 5 Delenex Therapeutics AG - Research and Development Overview 6 Key Therapeutic Areas 6 Delenex Therapeutics AG - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Delenex Therapeutics AG - Pipeline Products Glance 11 Delenex Therapeutics AG - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Delenex Therapeutics AG - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Delenex Therapeutics AG - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Delenex Therapeutics AG - Drug Profiles 16 DLX-1008 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 DLX-105 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 DLX-2323 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 DLX-2681 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 DLX-2751 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 DLX-2882 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 DLX-2907 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 DLX-2909 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 DLX-2201 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Monoclonal Antibody Conjugate for Oncology and Inflammation 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Monoclonal Antibody for Oncology and Inflammation 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Delenex Therapeutics AG - Pipeline Analysis 29 Delenex Therapeutics AG - Pipeline Products by Target 29 Delenex Therapeutics AG - Pipeline Products by Route of Administration 30 Delenex Therapeutics AG - Pipeline Products by Molecule Type 31 Delenex Therapeutics AG - Pipeline Products by Mechanism of Action 32 Delenex Therapeutics AG - Recent Pipeline Updates 33 Delenex Therapeutics AG - Dormant Projects 34 Delenex Therapeutics AG - Locations And Subsidiaries 35 Head Office 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37

List of Tables Delenex Therapeutics AG, Key Information 5 Delenex Therapeutics AG, Key Facts 5 Delenex Therapeutics AG - Pipeline by Indication, 2016 7 Delenex Therapeutics AG - Pipeline by Stage of Development, 2016 9 Delenex Therapeutics AG - Monotherapy Products in Pipeline, 2016 10 Delenex Therapeutics AG - Phase III, 2016 11 Delenex Therapeutics AG - Phase II, 2016 12 Delenex Therapeutics AG - Phase I, 2016 13 Delenex Therapeutics AG - Preclinical, 2016 14 Delenex Therapeutics AG - Discovery, 2016 15 Delenex Therapeutics AG - Pipeline by Target, 2016 29 Delenex Therapeutics AG - Pipeline by Route of Administration, 2016 30 Delenex Therapeutics AG - Pipeline by Molecule Type, 2016 31 Delenex Therapeutics AG - Pipeline Products by Mechanism of Action, 2016 32 Delenex Therapeutics AG - Recent Pipeline Updates, 2016 33 Delenex Therapeutics AG - Dormant Developmental Projects,2016 34 List of Figures Delenex Therapeutics AG - Pipeline by Top 10 Indication, 2016 7 Delenex Therapeutics AG - Pipeline by Stage of Development, 2016 9 Delenex Therapeutics AG - Monotherapy Products in Pipeline, 2016 10 Delenex Therapeutics AG - Pipeline by Target, 2016 29 Delenex Therapeutics AG - Pipeline by Route of Administration, 2016 30 Delenex Therapeutics AG - Pipeline by Molecule Type, 2016 31 Delenex Therapeutics AG - Pipeline Products by Mechanism of Action, 2016 32